The benefit of radium-223 compared with placebo was seen in both docetaxel subgroups for most main secondary efficacy endpoints ; risk for time to time to first symptomatic skeletal event was reduced with radium-223 versus placebo in patients with previous docetaxel use , but the difference was not significant in those with no previous docetaxel use .